1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35402
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFay K.en
dc.contributor.authorCoyle L.en
dc.contributor.authorMackinlay N.en
dc.contributor.authorEnjeti A.en
dc.contributor.authorStevenson W.en
dc.contributor.authorShortt J.en
dc.contributor.authorArthur C.en
dc.contributor.authorJeffrey A.en
dc.contributor.authorYip E.en
dc.contributor.authorKatsioulas V.en
dc.contributor.authorNalpantidis A.en
dc.contributor.authorKerridge I.en
dc.contributor.authorGreenwood M.en
dc.date.accessioned2021-05-14T11:57:38Zen
dc.date.available2021-05-14T11:57:38Zen
dc.date.copyright2020en
dc.date.created20200415en
dc.date.issued2020-04-15en
dc.identifier.citationLeukemia and Lymphoma. 61 (4) (pp 831-839), 2020. Date of Publication: 20 Mar 2020.en
dc.identifier.issn1042-8194en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/35402en
dc.description.abstractThe prognosis of AML in elderly patients is poor and research into novel therapeutic approaches is urgently needed. This study examined the use of low-dose chemotherapy with cytarabine and thioguanine administered in repetitive cycles in 62 elderly patients with newly diagnosed or relapsed/refractory AML. The overall response rate was 58% in the total cohort. Response rates (CR/CRi) were significantly higher in patients with newly diagnosed AML (74%) compared to patients with relapsed/refractory disease (25%, p =.0004). Kaplan-Meier estimate of overall survival was 289 days (95% CI; 183-395 days) with a relapse rate of 65.7%. The induction mortality rate was 16.1% with treatment successfully undertaken in the outpatient setting. Similar clinical outcomes were observed in a retrospective analysis of a second cohort of 25 AML patients treated at a different site. These results support the use of a sustained low intensity chemotherapy approach as a therapeutic option for elderly patients with AML.Copyright © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.en
dc.languageEnglishen
dc.languageenen
dc.publisherTaylor and Francis Ltden
dc.relation.ispartofLeukemia and Lymphomaen
dc.subject.meshaged-
dc.subject.meshcancer-
dc.subject.meshcancer survival-
dc.subject.meshconsolidation chemotherapy-
dc.subject.meshfaintness-
dc.subject.meshfebrile neutropenia-
dc.subject.meshgastrointestinal hemorrhage-
dc.subject.meshheart arrhythmia-
dc.subject.meshinduction chemotherapy-
dc.subject.meshleukemia remission-
dc.subject.meshlow drug dose-
dc.subject.meshlung edema-
dc.subject.meshmaintenance chemotherapy-
dc.subject.meshmultimodal chemotherapy-
dc.subject.meshoutpatient-
dc.subject.meshphase 2-
dc.subject.meshpneumonia-
dc.subject.meshrecurrence risk-
dc.subject.meshthorax pain-
dc.subject.meshvalidation study-
dc.subject.meshazacitidine-
dc.subject.meshcytarabine/ct-
dc.subject.meshcytarabine/ad-
dc.subject.meshcytarabine-
dc.subject.meshcytarabine/sc [Subcutaneous Drug Administration]-
dc.subject.meshtioguanine/ct-
dc.subject.meshtioguanine/ad-
dc.subject.meshtioguanine-
dc.subject.meshacute kidney failure-
dc.subject.meshacute myeloid leukemia-
dc.titleProlonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.en
dc.typeArticleen
dc.identifier.affiliationHaematology-
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/10428194.2019.1697876-
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid31809629 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31809629]en
dc.identifier.source2003837877en
dc.identifier.institution(Arthur, Jeffrey, Yip, Katsioulas, Kerridge, Greenwood, Coyle, Mackinlay, Fay, Stevenson) Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St Leonards, Sydney, Australia (Nalpantidis, Shortt) Department of Clinical Haematology, Monash Health, Clayton, Australia (Kerridge, Greenwood, Stevenson) Department of Medicine, University of Sydney, Sydney, Australia (Enjeti) Department of Haematology, Pathology North, John Hunter Hospital, Newcastle, Australia (Shortt) School of Clinical Sciences at Monash Health, Monash University, Clayton, Australiaen
dc.description.addressW. Stevenson, Department of Haematology, Royal North Shore Hospital, St Leonards, Sydney 2065, Australia. E-mail: william.stevenson@sydney.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordsacute myeloid leukemia cytarabine Low-dose chemotherapy thioguanineen
dc.identifier.authoremailStevenson W.; william.stevenson@sydney.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

42
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.